Advertisement

Targeted Oncology

, Volume 10, Issue 1, pp 153–170 | Cite as

Gefitinib: a review of its use in adults with advanced non-small cell lung cancer

  • Sohita DhillonEmail author
ADIS DRUG EVALUATION

Abstract

Gefitinib (Iressa®) is a selective small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR TKI) indicated for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR tyrosine kinase. Large phase III or IV clinical trials in patients with locally advanced or metastatic NSCLC showed that gefitinib as first- or subsequent-line treatment significantly prolonged progression-free survival (PFS) and improved objective response rates and/or health-related quality of life parameters in patients with activating EGFR mutations and in clinically selected patients (e.g., Asian patients or never-smokers) who are more likely to harbour these mutations. Overall survival did not increase significantly with gefitinib, although post-study treatments may have had a confounding effect on this outcome. Gefitinib was generally well tolerated in these studies, with mild or moderate skin reactions, gastrointestinal disturbances and elevations in liver enzymes among the most common adverse reactions in gefitinib recipients; interstitial lung disease has also been reported in <6 % of gefitinib recipients. Compared with chemotherapy, gefitinib as first- or subsequent-line therapy provided similar or greater PFS benefit and was generally associated with fewer haematological adverse events, neurotoxicity, asthenic disorders, as well as grade ≥3 adverse events. Although the position of gefitinib with respect to other EGFR TKIs is not definitively established, current evidence indicates that gefitinib monotherapy is an effective and generally well-tolerated first- or subsequent-line treatment option for patients with NSCLC and activating EGFR mutations who have not received an EGFR TKI previously.

Keywords

Gefitinib Epidermal growth factor receptor tyrosine kinase inhibitor Non-small cell lung cancer 

Notes

Data selection sources

Relevant medical literature (including published and unpublished data) on gefitinib was identified by searching databases including MEDLINE (from 1946) and EMBASE (from 1996) [searches last updated 16 January 2015], bibliographies from published literature, clinical trial registries/databases and websites. Additional information was also requested from the company developing the drug.

Search terms

Gefitinib, non-small cell lung cancer, NSCLC, EGFR-mutation positive, locally advanced, metastatic, first-line, second-line.

Study selection

Studies in patients with locally advanced or metastatic non-small cell lung cancer who received gefitinib as first-line or subsequent-line therapy. When available, large, well-designed, comparative trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit. Sohita Dhillon is a salaried employee of Adis/Springer.

References

  1. 1.
    Kohler J, Schuler M (2013) Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review. Onkologie 36(9):510–8CrossRefPubMedGoogle Scholar
  2. 2.
    Herbst RS, Bunn PA Jr (2003) Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 9(16 Pt 1):5813–24PubMedGoogle Scholar
  3. 3.
    Spiro SG, Silvestri GA (2005) One hundred years of lung cancer. Am J Respir Crit Care Med 172(5):523–9CrossRefPubMedGoogle Scholar
  4. 4.
    Weinstein IB, Joe AK (2006) Mechanisms of disease: oncogene addiction—a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3(8):448–57CrossRefPubMedGoogle Scholar
  5. 5.
    Zhang Z, Stiegler AL, Boggon TJ et al (2010) EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget 1(7):497–514PubMedCentralPubMedGoogle Scholar
  6. 6.
    Johnston JB, Navaratnam S, Pitz MW et al (2006) Targeting the EGFR pathway for cancer therapy. Curr Med Chem 13(29):3483–92CrossRefPubMedGoogle Scholar
  7. 7.
    Seshacharyulu P, Ponnusamy MP, Haridas D et al (2012) Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 16(1):15–31CrossRefPubMedCentralPubMedGoogle Scholar
  8. 8.
    European Medicines Agency (2014) Iressa (gefitinib): summary of product characteristics. http://www.ema.europa.eu. Accessed 28 Jan 2015
  9. 9.
    Zhang X, Chang A (2008) Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. Int J Med Sci 5(4):209–17CrossRefPubMedCentralPubMedGoogle Scholar
  10. 10.
    Nurwidya F, Takahashi F, Murakami A et al (2014) Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Respir Investig 52(2):82–91CrossRefPubMedGoogle Scholar
  11. 11.
    Tartarone A, Lazzari C, Lerose R et al (2013) Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib. Lung Cancer 81(3):328–36CrossRefPubMedGoogle Scholar
  12. 12.
    Ohashi K, Maruvka YE, Michor F et al (2013) Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol 31(8):1070–80CrossRefPubMedCentralPubMedGoogle Scholar
  13. 13.
    Sanford M, Scott LJ (2009) Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer. Drugs 69(16):2303–28CrossRefPubMedGoogle Scholar
  14. 14.
    Kobayashi K, Hagiwara K (2013) Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC). Target Oncol 8(1):27–33CrossRefPubMedCentralPubMedGoogle Scholar
  15. 15.
    Bronte G, Rolfo C, Giovannetti E et al (2014) Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. Crit Rev Oncol Hematol 89(2):300–13CrossRefPubMedGoogle Scholar
  16. 16.
    Wakeling AE, Guy SP, Woodburn JR et al (2002) ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62(20):5749–54PubMedGoogle Scholar
  17. 17.
    Albanell J, Rojo F, Averbuch S et al (2002) Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20(1):110–24CrossRefPubMedGoogle Scholar
  18. 18.
    Baselga J, Rischin D, Ranson M et al (2002) Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20(21):4292–302CrossRefPubMedGoogle Scholar
  19. 19.
    Ciardiello F, Caputo R, Bianco R et al (2001) Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7(5):1459–65PubMedGoogle Scholar
  20. 20.
    Nakagawa K, Tamura T, Negoro S et al (2003) Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 14(6):922–30CrossRefPubMedGoogle Scholar
  21. 21.
    Herbst RS, Maddox AM, Rothenberg ML et al (2002) Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 20(18):3815–25CrossRefPubMedGoogle Scholar
  22. 22.
    Ranson M, Hammond LA, Ferry D et al (2002) ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 20(9):2240–50CrossRefPubMedGoogle Scholar
  23. 23.
    Kris MG, Natale RB, Herbst RS et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290(16):2149–58CrossRefPubMedGoogle Scholar
  24. 24.
    Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial). J Clin Oncol 21(12):2237–46CrossRefPubMedGoogle Scholar
  25. 25.
    Shigematsu H, Lin L, Takahashi T et al (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97(5):339–46CrossRefPubMedGoogle Scholar
  26. 26.
    Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497–500CrossRefPubMedGoogle Scholar
  27. 27.
    Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129–39CrossRefPubMedGoogle Scholar
  28. 28.
    Pao W, Miller V, Zakowski M et al (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101(36):13306–11CrossRefPubMedCentralPubMedGoogle Scholar
  29. 29.
    Tanaka T, Matsuoka M, Sutani A et al (2010) Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer 126(3):651–5CrossRefPubMedGoogle Scholar
  30. 30.
    Cappuzzo F, Hirsch FR, Rossi E et al (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97(9):643–55CrossRefPubMedGoogle Scholar
  31. 31.
    Hirsch FR, Varella-Garcia M, McCoy J et al (2005) Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group study. J Clin Oncol 23(28):6838–45CrossRefPubMedGoogle Scholar
  32. 32.
    Hirsch FR, Varella-Garcia M, Bunn PA Jr et al (2006) Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 24(31):5034–42CrossRefPubMedGoogle Scholar
  33. 33.
    Douillard J-Y, Shepherd FA, Hirsh V et al (2010) Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 28(5):744–52CrossRefPubMedGoogle Scholar
  34. 34.
    Fukuoka M, Wu Y-L, Thongprasert S et al (2011) Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29(21):2866–74CrossRefPubMedGoogle Scholar
  35. 35.
    Yasuda H, Kobayashi S, Costa DB (2012) EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol 13(1):e23–31CrossRefPubMedGoogle Scholar
  36. 36.
    Faber AC, Corcoran RB, Ebi H et al (2011) BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov 1(4):352–65CrossRefPubMedCentralPubMedGoogle Scholar
  37. 37.
    Kobayashi S, Boggon TJ, Dayaram T et al (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352(8):786–92CrossRefPubMedGoogle Scholar
  38. 38.
    Engelman JA, Zejnullahu K, Mitsudomi T et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827):1039–43CrossRefPubMedGoogle Scholar
  39. 39.
    Yun CH, Mengwasser KE, Toms AV et al (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 105(6):2070–5CrossRefPubMedCentralPubMedGoogle Scholar
  40. 40.
    Li D, Ambrogio L, Shimamura T et al (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27(34):4702–11CrossRefPubMedCentralPubMedGoogle Scholar
  41. 41.
    Miller VA, Hirsh V, Cadranel J et al (2012) Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 13(5):528–38CrossRefPubMedGoogle Scholar
  42. 42.
    Chen X, Zhau JY, Zhao J et al (2013) Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells. Anticancer Drugs 24(10):1039–46CrossRefPubMedGoogle Scholar
  43. 43.
    Watanabe S, Tanaka J, Ota T, et al. (2011) Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis. BMC Cancer [Electronic Resource];11:1Google Scholar
  44. 44.
    Ellison G, Zhu G, Moulis A et al (2013) EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol 66(2):79–89CrossRefPubMedCentralPubMedGoogle Scholar
  45. 45.
    Kerr KM, Bubendorf L, Edelman MJ et al (2014) Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol 25(9):1681–90CrossRefPubMedGoogle Scholar
  46. 46.
    Yang JC, Wu YL, Chan V et al (2014) Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS). Lung Cancer 83(2):174–81CrossRefPubMedGoogle Scholar
  47. 47.
    Mok TS, Wu Y-L, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947–57CrossRefPubMedGoogle Scholar
  48. 48.
    Goto K, Ichinose Y, Ohe Y et al (2012) Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol 7(1):115–21CrossRefPubMedGoogle Scholar
  49. 49.
    Douillard JY, Ostoros G, Cobo M et al (2014) Gefitinib treatment in EGFR mutated Caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol 9(9):1345–53CrossRefPubMedCentralPubMedGoogle Scholar
  50. 50.
    Douillard JY, Ostoros G, Cobo M et al (2014) First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer 110(1):55–62CrossRefPubMedCentralPubMedGoogle Scholar
  51. 51.
    AstraZeneca (2014) IRESSA receives CHMP positive opinion to include blood based diagnostic testing in European label [media release]. 26 Sep. http://www.astrazeneca.com
  52. 52.
    Zhao J, Chen M, Zhong W et al (2013) Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma. Clin Lung Cancer 14(2):188–93CrossRefPubMedGoogle Scholar
  53. 53.
    Swaisland HC, Cantarini MV, Fuhr R et al (2006) Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics. Clin Pharmacokinet 45(6):633–44CrossRefPubMedGoogle Scholar
  54. 54.
    Motonaga M, Makino Y, Yamamoto N et al (2013) An analysis of the drug-drug interaction between docetaxel and gefitinib in patients with advanced non-small cell lung cancer [abstract no. P1.10-029]. J Thorac Oncol 8(Suppl 2):S575–S6Google Scholar
  55. 55.
    Chikamori K, Aoe K, Maeda T, et al. (2013) Impact of concomitant use of anti-acid agents on efficacy of gefitinib in EGFR-mutant non-small-cell lung cancer (NSCLC) [abstract no. e19008]. J Clin Oncol 31(15 Suppl 1)Google Scholar
  56. 56.
    Saeki S, Sasaki J, Morioka J, et al. (2012) The influence of gastric secretion inhibitors on gefitinib therapy in patients with non-small cell lung cancer harboring epidermal growth factor receptor activating mutations [abstract no. e18059]. J Clin Oncol 30(15 Suppl 1)Google Scholar
  57. 57.
    Sun J-M, Lee KH, Kim S-W et al (2012) Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial. Cancer 118(24):6234–42CrossRefPubMedGoogle Scholar
  58. 58.
    Han JY, Park K, Kim SW et al (2012) First-SIGNAL: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 30(10):1122–8CrossRefPubMedGoogle Scholar
  59. 59.
    Shi Y, Zhang L, Liu X et al (2013) Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol 14(10):953–61CrossRefPubMedGoogle Scholar
  60. 60.
    Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380–8CrossRefPubMedGoogle Scholar
  61. 61.
    Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121–8CrossRefPubMedGoogle Scholar
  62. 62.
    Inoue A, Kobayashi K, Usui K et al (2009) First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 27(9):1394–400CrossRefPubMedGoogle Scholar
  63. 63.
    Thatcher N, Chang A, Parikh P et al (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366(9496):1527–37CrossRefPubMedGoogle Scholar
  64. 64.
    National Cancer Institute (2014) Cellular classification of NSCLC. http://www.cancer.gov. Accessed 28 Jan 2015
  65. 65.
    Chang A, Parikh P, Thongprasert S et al (2006) Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 1(8):847–55CrossRefPubMedGoogle Scholar
  66. 66.
    Kim ES, Hirsh V, Mok T et al (2008) Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372(9652):1809–18CrossRefPubMedGoogle Scholar
  67. 67.
    Maruyama R, Nishiwaki Y, Tamura T et al (2008) Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 26(26):4244–52CrossRefPubMedGoogle Scholar
  68. 68.
    Lee DH, Park K, Kim JH et al (2010) Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 16(4):1307–14CrossRefPubMedGoogle Scholar
  69. 69.
    Sekine I, Ichinose Y, Nishiwaki Y et al (2009) Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel. Ann Oncol 20(9):1483–8CrossRefPubMedGoogle Scholar
  70. 70.
    Kosaka T, Yatabe Y, Endoh H et al (2004) Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64(24):8919–23CrossRefPubMedGoogle Scholar
  71. 71.
    Nishiyama A, Katakami N, Morita S et al (2014) Randomized phase III study comparing gefitinib (G) with erlotinib (E) in patients (pts) with previously treated advanced lung adenocarcinoma (LA): WJOG5108L [abstract no. 1271P]. Ann Oncol 25(4):iv447Google Scholar
  72. 72.
    Kim ST, Uhm JE, Lee J et al (2012) Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer 75(1):82–8CrossRefPubMedGoogle Scholar
  73. 73.
    Miller VA, Kris MG, Shah N et al (2004) Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22(6):1103–9CrossRefPubMedGoogle Scholar
  74. 74.
    Thongprasert S, Duffield E, Saijo N et al (2011) Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). J Thorac Oncol 6(11):1872–80CrossRefPubMedGoogle Scholar
  75. 75.
    Wu Y-L, Chu D-T, Han B et al (2012) Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China. Asia Pac J Clin Oncol 8(3):232–43CrossRefPubMedGoogle Scholar
  76. 76.
    Wu Y-L, Fukuoka M, Mok TSK et al (2013) Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study. Lung Cancer 81(2):280–7CrossRefPubMedGoogle Scholar
  77. 77.
    Inoue A, Kobayashi K, Maemondo M et al (2013) Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol 24(1):54–9CrossRefPubMedGoogle Scholar
  78. 78.
    Mitsudomi T, Morita S, Yatabe Y, et al. (2012) Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR) [abstract no. 7521]. J Clin Oncol 30(15 Suppl)Google Scholar
  79. 79.
    Oizumi S, Kobayashi K, Inoue A et al (2012) Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 trial. Oncologist 17(6):863–70CrossRefPubMedCentralPubMedGoogle Scholar
  80. 80.
    Takano T, Fukui T, Ohe Y et al (2008) EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol 26(34):5589–95CrossRefPubMedGoogle Scholar
  81. 81.
    Kim HS, Park K, Jun HJ et al (2009) Comparison of survival in advanced non-small cell lung cancer patients in the pre- and post-gefitinib eras. Oncology 76(4):239–46CrossRefPubMedGoogle Scholar
  82. 82.
    European Medicines Agency (2009) Assessment report for Iressa. http://www.ema.europa.eu. Accessed 28 Jan 2015
  83. 83.
    Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22(9):1589–97CrossRefPubMedGoogle Scholar
  84. 84.
    Kudoh S, Kato H, Nishiwaki Y et al (2008) Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 177(12):1348–57CrossRefPubMedGoogle Scholar
  85. 85.
    Akamatsu H, Inoue A, Mitsudomi T et al (2013) Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two phase III trials (NEJ 002 and WJTOG 3405). Jpn J Clin Oncol 43(6):664–8CrossRefPubMedGoogle Scholar
  86. 86.
    AstraZeneca KK (2011) Iressa (gefitinib): Japanese prescribing information. AstraZeneca KK, OsakaGoogle Scholar
  87. 87.
    Besse B, Adjei A, Baas P et al (2014) 2nd ESMO consensus conference on lung cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol 25(8):1475–84CrossRefPubMedGoogle Scholar
  88. 88.
    Reck M, Popat S, Reinmuth N et al (2014) Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(3):iii27–39CrossRefPubMedGoogle Scholar
  89. 89.
    Goto K, Satouchi M, Ishii G et al (2012) An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol 23(11):2914–9CrossRefPubMedGoogle Scholar
  90. 90.
    Reck M, Hagiwara K, Tjulandin S, et al. (2013) Investigating the utility of plasma-derived circulating-free DNA for the detection of EGFR mutations in European and Japanese patients with advanced NSCLC: ASSESS study design [abstract no. P1.06-022]. In: 15th World Conference on Lung CancerGoogle Scholar
  91. 91.
    Han B, Tjulandin S, Normanno N, et al. (2013) A diagnostic study to determine the prevalence of EGFR mutations in Asian and Russian patients with NSCLC of adenocarcinoma and non-adenocarcinoma histology: IGNITE study design [abstract no. P3.06-053]. In: 15th World Conference on Lung CancerGoogle Scholar
  92. 92.
    Shao Y-Y, Shau W-Y, Lin Z-Z et al (2013) Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer. Eur J Cancer 49(1):106–14CrossRefPubMedGoogle Scholar
  93. 93.
    Kim ST, Lee J, Kim J-H et al (2010) Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy. Cancer 116(12):3025–33CrossRefPubMedGoogle Scholar
  94. 94.
    Wu WS, Chen YM, Tsai CM et al (2012) Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations. Exp Ther Med 3(2):207–13PubMedCentralPubMedGoogle Scholar
  95. 95.
    Liang W, Wu X, Fang W et al (2014) Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. PLoS ONE 9(2):e85245CrossRefPubMedCentralPubMedGoogle Scholar
  96. 96.
    Mok TSK, Wu Y, Nakagawa SK, et al. (2014) Gefitinib/chemotherapy vs chemotherapy in epidermal growth factor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) after progression on first-line gefitinib: the phase III, randomised IMPRESS study [abstract no. LBA2-PR]. Ann Oncol 25(Suppl 5)Google Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations